218 related articles for article (PubMed ID: 30285425)
1. Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase.
Carnevale LN; Arango AS; Arnold WR; Tajkhorshid E; Das A
Biochemistry; 2018 Nov; 57(46):6489-6499. PubMed ID: 30285425
[TBL] [Abstract][Full Text] [Related]
2. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase.
McDougle DR; Kambalyal A; Meling DD; Das A
J Pharmacol Exp Ther; 2014 Dec; 351(3):616-27. PubMed ID: 25277139
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.
Arnold WR; Weigle AT; Das A
J Inorg Biochem; 2018 Jul; 184():88-99. PubMed ID: 29689453
[TBL] [Abstract][Full Text] [Related]
4. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.
Walker VJ; Griffin AP; Hammar DK; Hollenberg PF
J Pharmacol Exp Ther; 2016 Jun; 357(3):537-44. PubMed ID: 27000802
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Porter AC; Sauer JM; Knierman MD; Becker GW; Berna MJ; Bao J; Nomikos GG; Carter P; Bymaster FP; Leese AB; Felder CC
J Pharmacol Exp Ther; 2002 Jun; 301(3):1020-4. PubMed ID: 12023533
[TBL] [Abstract][Full Text] [Related]
7. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
Snider NT; Walker VJ; Hollenberg PF
Pharmacol Rev; 2010 Mar; 62(1):136-54. PubMed ID: 20133390
[TBL] [Abstract][Full Text] [Related]
8. Prediction of essential binding domains for the endocannabinoid N-arachidonoylethanolamine (AEA) in the brain cannabinoid CB1 receptor.
Shim JY
PLoS One; 2021; 16(6):e0229879. PubMed ID: 34181638
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner.
Barana A; Amorós I; Caballero R; Gómez R; Osuna L; Lillo MP; Blázquez C; Guzmán M; Delpón E; Tamargo J
Cardiovasc Res; 2010 Jan; 85(1):56-67. PubMed ID: 19689982
[TBL] [Abstract][Full Text] [Related]
10. CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control.
Leow JWH; Chan ECY
Pharmacol Ther; 2024 Jun; 258():108637. PubMed ID: 38521247
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.
Pisanti S; Borselli C; Oliviero O; Laezza C; Gazzerro P; Bifulco M
J Cell Physiol; 2007 May; 211(2):495-503. PubMed ID: 17192847
[TBL] [Abstract][Full Text] [Related]
12. The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.
Oz M; Jaligam V; Galadari S; Petroianu G; Shuba YM; Shippenberg TS
J Neurochem; 2010 Mar; 112(6):1454-64. PubMed ID: 20050977
[TBL] [Abstract][Full Text] [Related]
13. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors.
Maccarrone M; Lorenzon T; Bari M; Melino G; Finazzi-Agro A
J Biol Chem; 2000 Oct; 275(41):31938-45. PubMed ID: 10913156
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid metabolism by cytochrome P450 monooxygenases.
Zelasko S; Arnold WR; Das A
Prostaglandins Other Lipid Mediat; 2015; 116-117():112-23. PubMed ID: 25461979
[TBL] [Abstract][Full Text] [Related]
15. Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia.
Amoako AA; Marczylo TH; Marczylo EL; Elson J; Willets JM; Taylor AH; Konje JC
Hum Reprod; 2013 Aug; 28(8):2058-66. PubMed ID: 23697839
[TBL] [Abstract][Full Text] [Related]
16. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner.
Amorós I; Barana A; Caballero R; Gómez R; Osuna L; Lillo MP; Tamargo J; Delpón E
J Mol Cell Cardiol; 2010 Jan; 48(1):201-10. PubMed ID: 19616555
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis.
Pasquariello N; Catanzaro G; Marzano V; Amadio D; Barcaroli D; Oddi S; Federici G; Urbani A; Finazzi Agrò A; Maccarrone M
J Biol Chem; 2009 Oct; 284(43):29413-26. PubMed ID: 19690173
[TBL] [Abstract][Full Text] [Related]
18. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
Di Marzo V; Melck D; Orlando P; Bisogno T; Zagoory O; Bifulco M; Vogel Z; De Petrocellis L
Biochem J; 2001 Aug; 358(Pt 1):249-55. PubMed ID: 11485574
[TBL] [Abstract][Full Text] [Related]
19. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors.
Xiong W; Wu X; Li F; Cheng K; Rice KC; Lovinger DM; Zhang L
J Neurosci; 2012 Apr; 32(15):5200-8. PubMed ID: 22496565
[TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries.
Stanley CP; Hind WH; Tufarelli C; O'Sullivan SE
Pharmacol Res; 2016 Nov; 113(Pt A):356-363. PubMed ID: 27633407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
